Voyager Therapeutics, Inc. - 8-K Filing
Voyager Therapeutics announced that the FDA cleared its Investigational New Drug application for VY1706, a tau silencing gene therapy targeting Alzheimer's disease. The company plans to initiate a multi-site clinical trial in Q2 2026 with up to 18 patients across three cohorts. (Items: 8.01 Other Events)
Tickers: $VYGR